GT Apeiron Therapeutics
Shanghai
About GT Apeiron Therapeutics
GT Apeiron Therapeutics is a developer of innovative drugs utilizing artificial intelligence technology. The company develops breakthrough investigational medicines by harnessing the power of artificial intelligence, aiming to drastically increase efficiency throughout the drug discovery process.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $44.5M
- Funding stage: Early Stage Venture
- Last round: Series A (Mar 2022)
- Website: apeiron-bio.com
Industries & Categories
Artificial Intelligence (AI), Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/gt-apeiron-therapeutics-46050 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.